DOCSLIB.ORG

The Characterization and Role of RREB1 in Human Bladder Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Characterization and Role of RREB1 in Human Bladder Cancer The Characterization and Role of RREB1 in Human Bladder Cancer Matthew David Nitz Sebring, Fl B.S. Wheaton College, 2003 M.S ., University of Virginia, 2009 A Dissertation presented to the Graduate Faculty of the University of Virginia in Cand idacy for the Degree of Doctor of Philosophy Department of Molecular Physiology and Biological Physics University of Virginia August, 2011 I Abstract RREB1 is a C2H2 zinc-finger protein that has previously been associated with malignancy but little is known about its expression, composition of splice variants, or role in cancer phenotypes. Total RREB1 expression decreased in human bladder cancer tumors compared to paired normal tissue. Rigorous comparison of commercial RREB1 antibodies allowed for the identification of RREB1 splice variants in the cytoplasm and nucleus on western blot. Five RREB1 splice variants were identified and designated: RREB1α, RREB1β, RREB1γ, RREB1δ, RREB1ε. Immunohistochemistry of RREB1 in a bladder cancer tissue microarray demonstrated that RREB1 expression positively correlates with the squamous cell histology. Transient depletion of RREB1 in bladder cancer cell lines (UMUC3 and KU7) decreased cell growth in vitro and similar results were seen in prostate cancer cell lines (LNCAP and PC3). siRNA duplexes that target RREB1 isoforms showed RREB1α and RREB1β, but not RREB1β alone, were necessary for in vitro UMUC3 cell growth and in vivo subcutaneous tumor growth. RREB1 depletion was found to decrease the expression of tumor associated protein CD24. Cloning of the CD24 promoter revealed a hypoxia response element, which led to the discovery of hypoxia induced CD24 RNA expression and promoter activity. RREB1 depletion decreased the expression of two additional hypoxia responsive genes (VEGFA and IGFBP3) without affecting the mRNA stability. Loss of RREB1 was found to reduce HIF1A protein levels and decrease its occupancy of the CD24 promoter. II Depletion of HIF1A caused a similar degree of cell growth inhibition as seen with RREB1 depletion. Thus, we propose the necessity of RREB1 in urologic malignancies at least partially acts by the stabilization of HIF1A protein and maintenance of downstream gene expression. III Table of Contents Abstract ............................................................................................................................... I Table of Contents ............................................................................................................. III List of Figures ................................................................................................................... V List of Tables ................................................................................................................... VII General Acknowledgments .......................................................................................... VIII Chapter 1: Introduction .....................................................................................................1 1.1 The Clinical Manifestation of Bladder Cancer .................................................................... 1 1.2 Molecular Insights into Bladder Cancer Progression ........................................................ 9 Chapter 2: The characterization of alternatively spliced RREB1 ............................... 27 2.1 Abstract .................................................................................................................................. 28 2.2 Introduction ............................................................................................................................ 29 2.3 Materials and Methods ........................................................................................................ 30 2.4 Results ................................................................................................................................... 34 2.5 Discussion ............................................................................................................................. 57 2.6 Acknowledgements .............................................................................................................. 65 Chapter 3: The Role of RREB1 in Bladder Cancer ....................................................... 66 3.1 Abstract .................................................................................................................................. 67 3.2 Introduction ............................................................................................................................ 68 3.3 Materials and Methods ........................................................................................................ 70 3.4 Results ................................................................................................................................... 74 3.5 Discussion ............................................................................................................................. 94 Chapter 4: Ral, RREB1, and Hypoxia Regulation of the CD24 Promoter ................. 96 4.1 Abstract .................................................................................................................................. 97 4.2 Introduction ............................................................................................................................ 98 4.3 Materials and Methods ...................................................................................................... 103 4.4 Results ................................................................................................................................. 106 IV 4.5 Discussion ........................................................................................................................... 131 Chapter 5: RREB1 binds and stabilizes the HIF1A transcription factor ................. 135 5.1 Abstract ................................................................................................................................ 136 5.2 Introduction .......................................................................................................................... 137 5.3 Materials and Methods ...................................................................................................... 139 5.4 Results ................................................................................................................................. 143 5.5 Discussion ........................................................................................................................... 163 Chapter 6: Discussion ................................................................................................... 165 6.1 RREB1 in bladder and prostate cancer........................................................................... 165 6.2 Defining CD24 transcriptional control .............................................................................. 178 6.3 Defining the interaction between RREB1 and HIF1A ................................................... 186 6.4 Future Directions of RREB1 .............................................................................................. 191 Chapter 7: References ................................................................................................... 195 V List of Figures Figure Page Figure 1: Low and high grade papillary carcinoma ......................................... 8 Figure 2: Bladder cancer treatment diagram ................................................. 12 Figure 3: Cycling of Ras GTPase .................................................................... 14 Figure 4: The HIF1A Pathway .......................................................................... 24 Figure 5: RREB1 alternative splicing .............................................................. 37 Figure 6: Detection of RREB1 isoforms ......................................................... 39 Figure 7: A novel RREB1 splice variant ......................................................... 42 Figure 8: RREB1 expression in cell lines ....................................................... 44 Figure 9: RREB1 expression in tumors .......................................................... 47 Figure 10: Overexpressed RREB1 protein isoforms ..................................... 49 Figure 11: Endogenous RREB1 protein isoforms ......................................... 53 Figure 12: RREB1 immunohistochemistry ..................................................... 56 Figure 13: RREB1 tissue microarray legend .................................................. 60 Figure 14: RREB1 TMA clinical associations ................................................. 62 Figure 15: RREB1 dependent growth ............................................................. 77 Figure 16: RREB1 splice variant rescue ......................................................... 79 Figure 17: RREB1 splice variant dependent growth ..................................... 84 Figure 18: Non-targeted RREB1 splice variant upregulation ........................ 87 Figure 19: RREB1 depletion xenograft tumorigenesis .................................. 91 Figure 20: RREB1delta drives xenograft tumorigenesis ............................... 93 VI Figure 21: Proposed CD24 promoter regulation .......................................... 102 Figure 22: CD24 expression is dependent on RREB1 ................................. 109 Figure 23: CD24 rescue of RREB1 depletion ............................................... 112 Figure
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Evaluating the Gene Targets of Micrornas Associated with Parkinson's Disease
    Evaluating the Gene Targets of microRNAs Associated with Parkinson’s Disease Kimberly Horn and Michael Sierk Bioinformatics Program, Saint Vincent College, Latrobe, PA Abstract Background: microRNA Gene Prediction Databases Results: Databases’ microRNA Predictions Results: Repeated Gene Target Predictions Cont. Almost 10 million people in the world's population are living with The top gene targets that were predicted for multiple Parkinson's disease and can only be officially diagnosed by miRNAs were selected in RStudio by grouping all the miRNAs’ symptoms. Parkinson's disease is a neurological disorder that https://academic.oup.com/nar/article/37/suppl_2/W266/1147920 prediction results by what gene target was predicted. This resulted does not display symptoms until significant nerve damage is in groups of predictions for each target, regardless of the miRNA. These groups were counted and the ten targets with the highest done. There is a need for biological testing to allow an earlier ElMMo is a Bayesian based gene prediction program that number of predictions were used to produce figure 4. Table 1 lists diagnosis. MicroRNAs are involved in messenger RNA translation focuses on genomics comparison to predict the gene targets. This each of the targets from figure 4 with the number of times they to protein as they control gene regulation. Abnormal levels of program focuses on the presence of potential gene targets in the were predicted and their gene function from UniProt. some microRNAs have been found in Parkinson's patients but the 3’ UTR site, compared to both the 3’ or 5’ sites. ElMMo is not In the miRNA target gene predictions, some genes were genes they regulate were unknown.
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • An Integrative Genomic Analysis of the Longshanks Selection Experiment for Longer Limbs in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/378711; this version posted August 19, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Title: 2 An integrative genomic analysis of the Longshanks selection experiment for longer limbs in mice 3 Short Title: 4 Genomic response to selection for longer limbs 5 One-sentence summary: 6 Genome sequencing of mice selected for longer limbs reveals that rapid selection response is 7 due to both discrete loci and polygenic adaptation 8 Authors: 9 João P. L. Castro 1,*, Michelle N. Yancoskie 1,*, Marta Marchini 2, Stefanie Belohlavy 3, Marek 10 Kučka 1, William H. Beluch 1, Ronald Naumann 4, Isabella Skuplik 2, John Cobb 2, Nick H. 11 Barton 3, Campbell Rolian2,†, Yingguang Frank Chan 1,† 12 Affiliations: 13 1. Friedrich Miescher Laboratory of the Max Planck Society, Tübingen, Germany 14 2. University of Calgary, Calgary AB, Canada 15 3. IST Austria, Klosterneuburg, Austria 16 4. Max Planck Institute for Cell Biology and Genetics, Dresden, Germany 17 Corresponding author: 18 Campbell Rolian 19 Yingguang Frank Chan 20 * indicates equal contribution 21 † indicates equal contribution 22 Abstract: 23 Evolutionary studies are often limited by missing data that are critical to understanding the 24 history of selection. Selection experiments, which reproduce rapid evolution under controlled 25 conditions, are excellent tools to study how genomes evolve under strong selection. Here we 1 bioRxiv preprint doi: https://doi.org/10.1101/378711; this version posted August 19, 2018.
    [Show full text]
  • MRTFB Suppresses Colorectal Cancer Development Through Regulating SPDL1 and MCAM
    MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM Takahiro Kodamaa,b,c, Teresa A. Mariana,b, Hubert Leea, Michiko Kodamaa, Jian Lid, Michael S. Parmacekd, Nancy A. Jenkinsa,e, Neal G. Copelanda,e,1, and Zhubo Weia,b,1 aHouston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030; bHouston Methodist Cancer Center, Houston Methodist Hospital, Houston, TX 77030; cDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, 5650871 Suita, Osaka, Japan; dDepartment of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104; and eGenetics Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 Contributed by Neal G. Copeland, October 7, 2019 (sent for review June 18, 2019; reviewed by Masaki Mori and Hiroshi Seno) Myocardin-related transcription factor B (MRTFB) is a candidate tumor- shown to regulate cell cycle progression (9) and HCC xenograft suppressor gene identified in transposon mutagenesis screens of the tumor growth (10). Functional validation using cell culture sys- intestine, liver, and pancreas. Using a combination of cell-based assays, tems have also shown that reduced expression of MRTFB by in vivo tumor xenograft assays, and Mrtfb knockout mice, we demon- RNA interference leads to increased CRC cell invasion (4), strate here that MRTFB is a human and mouse colorectal cancer suggesting its important role in tumor progression. (CRC) tumor suppressor that functions in part by inhibiting cell Based on these results, we decided to conditionally delete invasion and migration. To identify possible MRTFB transcriptional Mrtfb in the mouse intestine to further explore its role in CRC.
    [Show full text]
  • WO 2013/086478 Al 13 June 2013 (13.06.2013) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/086478 Al 13 June 2013 (13.06.2013) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every G01N33/574 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2012/068653 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 December 2012 (10. 12.2012) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 61/569,245 10 December 201 1 (10. 12.201 1) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: ABBOTT MOLECULAR INC. [US/US]; kind of regional protection available): ARIPO (BW, GH, 1300 E. Touhy Ave., Des Plaines, IL 60018 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: JEWELL, Susan; 440 Emery Lane, Elmhurst, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, IL 60126 (US).
    [Show full text]
  • Revised Manuscript ID CJP-2016-11-0031R1
    Page 1 of 64 The Journal of Pathology: Clinical Research Revised Manuscript ID CJP-2016-11-0031R1 HERRINGTON EDITED Fluorescence in situ Hybridization in Surgical Pathology: Principles and Applications Liang Cheng, 1,2 , Shaobo Zhang, 1, Lisha Wang, 3, Gregory T MacLennan, 4, Darrell D. Davidson, 1 1Department of Pathology and Laboratory Medicine, 2Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana; 3Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI; 4Departments of Pathology and Laboratory Medicine, Case Western Reserve University, Cleveland, Ohio. Running Head: FISH in Surgical Pathology Total number of text pages, 46; Number of tables, 2; Number of figures, 6. Address correspondence and reprint requests to Liang Cheng, M.D., Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11 th Street, IUHPL Room 4010, Indianapolis, IN 46202, USA. Telephone: 317-491-6442; Fax: 317-491-6419; E- mail: [email protected] Accepted Article This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version record. Please cite this article as doi:10.1002/cjp2.64. This article is protected by copyright. All rights reserved. The Journal of Pathology: Clinical Research Page 2 of 64 ABSTRACT Identification of recurrent tumour-specific chromosomal translocations and novel fusion oncogenes has important diagnostic, therapeutic, and prognostic implications. Over the past decade, fluorescence in situ hybridization (FISH) analysis of tumour samples has been one of the most rapidly growing areas in genomic medicine and surgical pathology practice.
    [Show full text]
  • Reverse Engineering of Ewing Sarcoma Regulatory Network Uncovers PAX7 and RUNX3 As Master Regulators Associated with Good Prognosis
    cancers Article Reverse Engineering of Ewing Sarcoma Regulatory Network Uncovers PAX7 and RUNX3 as Master Regulators Associated with Good Prognosis Marcel da Câmara Ribeiro-Dantas 1,2 , Danilo Oliveira Imparato 1 , Matheus Gibeke Siqueira Dalmolin 3 , Caroline Brunetto de Farias 3,4 , André Tesainer Brunetto 3 , Mariane da Cunha Jaeger 3,4 , Rafael Roesler 4,5 , Marialva Sinigaglia 3 and Rodrigo Juliani Siqueira Dalmolin 1,6,* 1 Bioinformatics Multidisciplinary Environment—IMD, Federal University of Rio Grande do Norte, Natal 59078-400, Brazil; [email protected] (M.d.C.R.-D.); [email protected] (D.O.I.) 2 Laboratoire Physico Chimie Curie, UMR168, Institut Curie, Université PSL, Sorbonne Université, 75005 Paris, France 3 Children’s Cancer Institute, Porto Alegre 90620-110, Brazil; [email protected] (M.G.S.D.); [email protected] (C.B.d.F.); [email protected] (A.T.B.); [email protected] (M.d.C.J.); [email protected] (M.S.) 4 Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE HCPA), Porto Alegre 90035-903, Brazil; [email protected] 5 Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Citation: Ribeiro-Dantas, M.d.C.; Porto Alegre 90050-170, Brazil 6 Imparato, D.O.; Dalmolin, M.G.S.; Department of Biochemistry—CB, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil * Correspondence: [email protected] de Farias, C.B.; Brunetto, A.T.; da Cunha Jaeger, M.; Roesler, R.; Sinigaglia, M.; Siqueira Dalmolin, R.J. Simple Summary: Ewing Sarcoma is a rare cancer that, when localized, has an overall five-year Reverse Engineering of Ewing survival rate of 70%.
    [Show full text]
  • The Transcription Factor Rreb1 Regulates Epithelial Architecture, Invasiveness, and Vasculogenesis in Early Mouse Embryos
    RESEARCH ARTICLE The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos Sophie M Morgani1,2*, Jie Su3, Jennifer Nichols2, Joan Massague´ 3, Anna-Katerina Hadjantonakis1* 1Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, United States; 2Wellcome Trust-Medical Research Council Centre for Stem Cell Research, University of Cambridge, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom; 3Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, United States Abstract Ras-responsive element-binding protein 1 (Rreb1) is a zinc-finger transcription factor acting downstream of RAS signaling. Rreb1 has been implicated in cancer and Noonan-like RASopathies. However, little is known about its role in mammalian non-disease states. Here, we show that Rreb1 is essential for mouse embryonic development. Loss of Rreb1 led to a reduction in the expression of vasculogenic factors, cardiovascular defects, and embryonic lethality. During gastrulation, the absence of Rreb1 also resulted in the upregulation of cytoskeleton-associated genes, a change in the organization of F-ACTIN and adherens junctions within the pluripotent epiblast, and perturbed epithelial architecture. Moreover, Rreb1 mutant cells ectopically exited the epiblast epithelium through the underlying basement membrane, paralleling cell behaviors observed during metastasis. Thus, disentangling the function of Rreb1 in development should shed *For correspondence: light on its role in cancer and other diseases involving loss of epithelial integrity. [email protected] (SMM); [email protected] (A-KH) Competing interests: The Introduction authors declare that no Ras-responsive element-binding protein 1 (RREB1) is a zinc-finger transcription factor that acts competing interests exist.
    [Show full text]
  • Occupancy Maps of 208 Chromatin-Associated Proteins In
    Article Occupancy maps of 208 chromatin- associated proteins in one human cell type https://doi.org/10.1038/s41586-020-2023-4 E. Christopher Partridge1,10, Surya B. Chhetri1,2,9,10, Jeremy W. Prokop1,3, Ryne C. Ramaker1,4, Camden S. Jansen5, Say-Tar Goh6, Mark Mackiewicz1, Kimberly M. Newberry1, Received: 4 October 2017 Laurel A. Brandsmeier1, Sarah K. Meadows1, C. Luke Messer1, Andrew A. Hardigan1,4, Accepted: 9 January 2020 Candice J. Coppola2, Emma C. Dean1,7, Shan Jiang5, Daniel Savic8, Ali Mortazavi5, Barbara J. Wold6, Richard M. Myers1 ✉ & Eric M. Mendenhall1,2 ✉ Published online: 29 July 2020 Open access Transcription factors are DNA-binding proteins that have key roles in gene Check for updates regulation1,2. Genome-wide occupancy maps of transcriptional regulators are important for understanding gene regulation and its efects on diverse biological processes3–6. However, only a minority of the more than 1,600 transcription factors encoded in the human genome has been assayed. Here we present, as part of the ENCODE (Encyclopedia of DNA Elements) project, data and analyses from chromatin immunoprecipitation followed by high-throughput sequencing (ChIP–seq) experiments using the human HepG2 cell line for 208 chromatin- associated proteins (CAPs). These comprise 171 transcription factors and 37 transcriptional cofactors and chromatin regulator proteins, and represent nearly one-quarter of CAPs expressed in HepG2 cells. The binding profles of these CAPs form major groups associated predominantly with promoters or enhancers, or with both. We confrm and expand the current catalogue of DNA sequence motifs for transcription factors, and describe motifs that correspond to other transcription factors that are co-enriched with the primary ChIP target.
    [Show full text]